MedTrace Logo

Probiotics and Capsaicin Evoked Coughs

NCT03603522 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-03-26

No results posted yet for this study

Summary

Cough in asthma is a very common and troublesome symptom in asthma, which predicts severity and poor prognosis. Previous studies have shown that asthmatics have an exaggerated cough response to capsaicin. Currently available asthma treatment is not designed to target the cough reflex directly, so this presents an unmet need for patients. The treatment being tested in this study is the commercially available over the counter oral probiotic BioGaia® DSM17938. Based on clinical and pre-clinical evidence, it is hypothesized that TRPV1 antagonism with BioGaia® DSM17938 will result in a reduction in capsaicin evoked coughs in patients with asthma.

Conditions

  • Atopic Asthma

Interventions

DIETARY_SUPPLEMENT

BioGaia-DSM17938

2mL per day (1x10\^9 CFU) per day taken orally for 28 days

OTHER

Placebo Comparator: Placebo Control

2mL per day of placebo formulation taken orally for 28 days

Sponsors & Collaborators

Principal Investigators

  • Gail Gauvreau, PhD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-16
Primary Completion
2021-01-18
Completion
2021-01-18

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03603522 on ClinicalTrials.gov